BioNTech SE: Clinical Trials

58 trials sponsored by BioNTech SE, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 18 recruiting, 11 terminated, 7 active not recruiting. 58 Phase 1, 35 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 158Completed 19, Recruiting 18, Terminated 11, Active not recruiting 7, Not yet recruiting 2, Withdrawn 1
Phase 235Recruiting 14, Terminated 10, Completed 7, Active not recruiting 3, Not yet recruiting 1

Follow BioNTech SE: new trials by email

Trials (filtered) newest first · largest first

All 58 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced Solid Tumors When Given Alone or Together With Other Investigational Drugs
BNT3219 - Advanced Solid Tumors
Phase 1Not yet recruitingBioNTech SE2072026-11-012026-10-23
A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn
BNT3210 - Advanced Solid Tumors
Phase 1 / Phase 2Not yet recruitingBioNTech SE1732026-11-012026-10-21
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
Obrixtamig, Pumitamig, Carboplatin - Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingBoehringer Ingelheim552026-10-012026-11-10
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
BNT168, Placebo - HIV -1 Infection
Phase 1RecruitingBioNTech SE1262026-08-042026-10-14
Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
BNT3214 - Advanced Solid Tumor Cancer
Phase 1 / Phase 2RecruitingBioNTech SE5332026-03-302026-08-13
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Pumitamig, Ipilimumab, Cabozantinib - Advanced Renal Cell Carcinoma (RCC)
Phase 1 / Phase 2RecruitingBristol-Myers Squibb4742026-03-262026-10-23
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Pumitamig, Ipilimumab - Hepatocellular Carcinoma (HCC)
Phase 1 / Phase 2RecruitingBristol-Myers Squibb1982026-03-162026-10-23
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
BNT351, Placebo - HIV -1 Infection
Phase 1RecruitingBioNTech SE672026-02-092026-09-01
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BNT329, CA19-9-targeting monoclonal antibody - Advanced Solid Cancers
Phase 1 / Phase 2RecruitingBioNTech SE2452025-11-182026-10-15
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
BNT326, Pumitamig - Non-small Cell Lung Cancer
Phase 1 / Phase 2RecruitingBioNTech SE8802025-09-222026-11-13
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
BNT3212, Pumitamig - Advanced Solid Tumor
Phase 1 / Phase 2RecruitingBioNTech SE3752025-08-272026-06-15
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
BNT326, Pumitamig, Itraconazole - Advanced Solid Tumor
Phase 1 / Phase 2RecruitingBioNTech SE14382025-08-122026-11-18
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
BNT314, Pumitamig, SoC chemotherapy treatment 1 - Metastatic Colorectal Cancer
Phase 1 / Phase 2RecruitingBioNTech SE4822025-07-182026-07-01
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
BNT324, BNT327 - Advanced Lung Cancer
Phase 1 / Phase 2RecruitingBioNTech SE5942025-05-022026-08-26
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
BNT323, BNT327 - Locally Advanced Breast Cancer, Unresectable Breast Carcinoma
Phase 1 / Phase 2RecruitingBioNTech SE3802025-04-232026-11-10
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine - Influenza, COVID-19 (Coronavirus Disease 2019)
Phase 1 / Phase 2CompletedBioNTech SE26502025-02-102026-01-26
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
BNT317 DL1, BNT317 DL2, BNT317 DL3 - Advanced Solid Tumor
Phase 1 / Phase 2RecruitingBioNTech SE2482025-01-132026-09-09
A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose - COVID-19
Phase 1WithdrawnBioNTech SE2025-01-062024-03-18
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine - Influenza,Human, COVID-19
Phase 1 / Phase 2CompletedBioNTech SE13532024-11-112026-08-19
A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis
BNT331, Placebo - Bacterial Vaginosis
Phase 1CompletedBioNTech SE1022024-07-012026-10-05

Showing 20 of 58. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (10)  ·  COVID-19 (7)  ·  Melanoma (5)  ·  Breast Neoplasms (4)  ·  Colorectal Neoplasms (4)  ·  Neoplasm Metastasis (4)  ·  Small Cell Lung Carcinoma (4)  ·  Stomach Neoplasms (4)  ·  Lethal Congenital Contracture Syndrome 2 (3)  ·  Neoplasms (3)  ·  Pancreatic Neoplasms (3)  ·  Virus Diseases (3)  ·  Bile Duct Neoplasms (2)  ·  Biliary Tract Neoplasms (2)  ·  Carcinoma, Hepatocellular (2)

Interventions

pembrolizumab (6)  ·  Carboplatin (5)  ·  Itraconazole (3)  ·  BNT162 Vaccine (2)  ·  Cisplatin (2)  ·  Etoposide (2)  ·  Fluorouracil (2)  ·  Gemcitabine (2)  ·  Injections (2)  ·  Ipilimumab (2)  ·  Paclitaxel (2)  ·  Ritonavir (2)  ·  atezolizumab (2)  ·  cemiplimab (2)  ·  130-nm albumin-bound paclitaxel (1)

Countries

United States (40)  ·  Spain (20)  ·  Germany (19)  ·  United Kingdom (17)  ·  Australia (14)  ·  China (14)  ·  France (7)  ·  Italy (7)  ·  Japan (6)  ·  Taiwan (6)  ·  Poland (5)  ·  South Korea (5)  ·  Turkey (Türkiye) (5)  ·  Belgium (4)  ·  Canada (4)

Top investigators

Lily Hu (2)  ·  Christian Ottensmeier, Prof (1)  ·  H. W. Nijman, MD/PhD (1)  ·  Inhye Ahn, MD (1)  ·  Ioannis Karydis, Dr (1)  ·  Neeta Pandit-Taskar, MD (1)  ·  Pierre-Yves Dietrich, Professor (1)  ·  Wolfgang Wick, Professor (1)

Results publications

PMID 40245769, PMID 42286358, PMID 32728218, PMID 35688554, PMID 35771353, PMID 36125366, PMID 37079651, PMID 37164012, PMID 37592303, PMID 37860278, PMID 38366591, PMID 38776391, PMID 39197299, PMID 39762422, PMID 40347227, PMID 41530185, PMID 41708868, PMID 42235570, PMID 42325270

NIH funding

2023 (8), 2025 (4), 2017 (2), 2018 (2), 2019 (2), 2014 (1)